Biologic Drug Analytics

Analytical Excellence for Biologics

ProtaGene is a CRO with extensive expertise in advanced method development, early to late-stage characterization, GMP product testing, and full analytical packages for product lifecycle management.

Talk to Our Team to Get Started

We’re well-staffed and positioned to support your established QC and high-volume programs and take on your most complex characterizations and method development programs.

"*" indicates required fields

Address*
This field is for validation purposes and should be left unchanged.

Comprehensive Analytical Solutions from Research to Market

We offer comprehensive capabilities and expertise to support every phase of a biologic’s lifecycle.

Diverse Biologic Therapeutics Platform Expertise

  • bullet Created with Sketch.

    Recombinant proteins—including complex, highly glycosylated proteins

  • bullet Created with Sketch.

    Multi-subunit Complexes—Protein, Nucleotide, Ligand

  • bullet Created with Sketch.

    mAbs

  • bullet Created with Sketch.

    ADCs and Protein Conjugates

  • bullet Created with Sketch.

    PEGylated Proteins

  • bullet Created with Sketch.

    Bispecifics/Multispecifics

  • bullet Created with Sketch.

    Fusion Proteins

  • bullet Created with Sketch.

    Enzyme Replacement Therapies

Why ProtaGene?

We collaborate with you to design a program customized for your molecule and the demands of your development timeline.
  • Unique development expertise in both protein and gene analytics
  • Broad single-vendor analytical offering from discovery to market
  • Significant scale of expertise & multi-region facility presence
  • Best-in-class quality supporting robust regulatory packages
  • Reputation and delivery trusted by leading biopharma companies
Learn More About ProtaGene

Subscribe to Our Email List

Talk to Our Experts

Leading global pharmaceutical organizations and emerging biopharma companies trust ProtaGene’s analytical excellence, deep experience, and quality systems to accelerate and de-risk their therapeutic development programs.

Contact Us